phone icon 1.866.CALL.MLH or 484.580.1000

Well Ahead Community

Main Line Hospital1.866.CALL.MLH Well Ahead Community

MLH Establishes Itself as Leader in Oncology Research

Albert DeNittis, MD, chief of Radiation Oncology, LMC, principal investigator of Main Line Health’s Community Clinical Oncology Program (CCOP) and CCOP member chairman to the NCI-funded Radiation Therapy Oncology Group, has been active in research projects that have spotlighted Main Line Health and its physicians and researchers.

The CCOP is a NCI-sponsored Cancer Clinical Trials Program. The program provides patients access to new cutting-edge treatments and symptoms management for cancer. The following activities are some of MLH’s accomplishments in the area of cancer research:
  • MLH has achieved national exposure by being the subject of two plenary papers discussed at September’s American Society of Radiation Oncology (ASTRO) meeting in Atlanta. Because of the system’s significant role in cancer research, MLH will be named on all ASTRO publications coming out in the near future. In addition to this recognition, all four of the program’s plenary sessions featured the results of RTOG research.
  •  

  • MLH CCOP was the leading national accruer on RTOG-0235, a study looking at survival in the non-small cell population. The results of this trial were published in the Journal of Clinical Oncology, the premier cancer journal in the world, in which Dr. DeNittis served as author. The article as entitled Predicton of Survival by [18F] Flurodeoxyglucose Positron Emission Tomography in Patients with Locally Advance Non-Small-Cell Lung Cancer Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668/RTOG 0235 Trial.
  •  

  • Dr. DeNittis recently presented, in collaboration with Drs. John Marks and Erik Zeger, on a radiation and microsurgery treatment that, combined with IMRT therapy, is only being done at LMC. The abstract, entitled Treatment of Distal Rectal Cancer with Preoperative Intensity Modulated Radiation Therapy (IMRT) Combined with Chemotherapy and Transanal Endoscopic Microsurgery: 5 Year Results of 12 patients, was published in the International Journal of Radiation Oncology, Biology and Physics. The group was also published in the Journal of Surgical Endoscopy in September for their research in assessing the role of minimally invasive surgery  after radiation and chemotherapy in the treatment of rectal cancer.
  •  

  • Collaborative efforts between LMC and Lankenau Institute for Medical Research have (LIMR) led to publication in a medical journal. The project, spearheaded by a Lankenau resident and published in the Journal of Radiation Oncology, assessed the role of immune surveillance and a single nucleotide polymorphism in the IDO2 gene and radiation response to the Whole Brain Radiotherapy and chloraquine. The IDO2 gene was discovered by George Prendergast, PhD., at LIMR.  
“The oncology research activities that Main Line Health has been involved in are truly remarkable,” said Dr. DeNittis. “Research plays such an important role in the fight against cancer. Discoveries in the lab lead to better treatments and better understanding of the hundreds of cancer diseases. Being part of a CCOP allows us to stay in the forefront of current treatment methodology. It is an honor for our researchers to have this national presence and reputation. I want to thank all of the CCOP staff and supporting clinicians who have helped make this program so successful.”

 
Posted by Main Line Health on 10/21/2013 12:44:42 PM
Read more articles about: Cancer, Lankenau, Albert_DeNittis_MD

MLH Establishes Itself as Leader in Oncology Research

Albert DeNittis, MD, chief of Radiation Oncology, LMC, principal investigator of Main Line Health’s Community Clinical Oncology Program (CCOP) and CCOP member chairman to the NCI-funded Radiation Therapy Oncology Group, has been active in research projects that have spotlighted Main Line Health and its physicians and researchers.

The CCOP is a NCI-sponsored Cancer Clinical Trials Program. The program provides patients access to new cutting-edge treatments and symptoms management for cancer. The following activities are some of MLH’s accomplishments in the area of cancer research:
  • MLH has achieved national exposure by being the subject of two plenary papers discussed at September’s American Society of Radiation Oncology (ASTRO) meeting in Atlanta. Because of the system’s significant role in cancer research, MLH will be named on all ASTRO publications coming out in the near future. In addition to this recognition, all four of the program’s plenary sessions featured the results of RTOG research.
  •  

  • MLH CCOP was the leading national accruer on RTOG-0235, a study looking at survival in the non-small cell population. The results of this trial were published in the Journal of Clinical Oncology, the premier cancer journal in the world, in which Dr. DeNittis served as author. The article as entitled Predicton of Survival by [18F] Flurodeoxyglucose Positron Emission Tomography in Patients with Locally Advance Non-Small-Cell Lung Cancer Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668/RTOG 0235 Trial.
  •  

  • Dr. DeNittis recently presented, in collaboration with Drs. John Marks and Erik Zeger, on a radiation and microsurgery treatment that, combined with IMRT therapy, is only being done at LMC. The abstract, entitled Treatment of Distal Rectal Cancer with Preoperative Intensity Modulated Radiation Therapy (IMRT) Combined with Chemotherapy and Transanal Endoscopic Microsurgery: 5 Year Results of 12 patients, was published in the International Journal of Radiation Oncology, Biology and Physics. The group was also published in the Journal of Surgical Endoscopy in September for their research in assessing the role of minimally invasive surgery  after radiation and chemotherapy in the treatment of rectal cancer.
  •  

  • Collaborative efforts between LMC and Lankenau Institute for Medical Research have (LIMR) led to publication in a medical journal. The project, spearheaded by a Lankenau resident and published in the Journal of Radiation Oncology, assessed the role of immune surveillance and a single nucleotide polymorphism in the IDO2 gene and radiation response to the Whole Brain Radiotherapy and chloraquine. The IDO2 gene was discovered by George Prendergast, PhD., at LIMR.  
“The oncology research activities that Main Line Health has been involved in are truly remarkable,” said Dr. DeNittis. “Research plays such an important role in the fight against cancer. Discoveries in the lab lead to better treatments and better understanding of the hundreds of cancer diseases. Being part of a CCOP allows us to stay in the forefront of current treatment methodology. It is an honor for our researchers to have this national presence and reputation. I want to thank all of the CCOP staff and supporting clinicians who have helped make this program so successful.”

 
Posted by Main Line Health on 10/21/2013 12:44:42 PM
Read more articles about: Cancer, Lankenau, Albert_DeNittis_MD
previous  1   next Results 1 - 1 of 1
 
 
Comments
Blog post currently doesn't have any comments.
Leave comment



Enter security code:
 Security code
 
FacebooktwitterYoutube